$-0.67 EPS Expected for Millendo Therapeutics, Inc. (MLND)

Analysts expect Millendo Therapeutics, Inc. (NASDAQ:MLND) to report $-0.67 EPS on May, 9.They anticipate $2.18 EPS change or 76.49 % from last quarter’s $-2.85 EPS. The stock increased 0.12% or $0.02 during the last trading session, reaching $16.32. About 10,808 shares traded. Millendo Therapeutics, Inc. (NASDAQ:MLND) has declined 10.05% since May 8, 2018 and is downtrending. It has underperformed by 14.42% the S&P500.

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company has market cap of $218.00 million. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. It currently has negative earnings.

More notable recent Millendo Therapeutics, Inc. (NASDAQ:MLND) news were published by: Streetinsider.com which released: “Stock to Watch: Millendo Therapeutics Inc. (MLND) is Marketing on an NDR with Leerink – StreetInsider.com” on April 25, 2019, also Seekingalpha.com with their article: “2 Preferred Stocks Offering 9% Yields – Seeking Alpha” published on May 06, 2017, Benzinga.com published: “Earnings Scheduled For April 3, 2019 – Benzinga” on April 03, 2019. More interesting news about Millendo Therapeutics, Inc. (NASDAQ:MLND) were released by: Gurufocus.com and their article: “Apr 08, 2019 – Loring Wolcott & Coolidge Fiduciary Advisors Llp Buys Amazon.com Inc, Adobe Inc, HDFC Bank, Sells Celgene Corp, Novo Nordisk A/S, Colgate-Palmolive Co – GuruFocus.com” published on April 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Dana Expands Portfolio With Acquisition of Oerlikon’s Segment – Yahoo Finance” with publication date: March 01, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.